Source comparison
CJC-1295 no DAC & Ipamorelin Results Timeline: Dosage, Frequency, and Outcome Comparison
Protocol design significantly impacts the CJC-1295 no DAC & Ipamorelin results timeline. Here's how different dosing strategies and administration frequencies affect endpoint expression: CJC-1295 no DAC 100 mcg + Ipamorelin 100 mcg once daily (pre-sleep) Singl
This comparison does not assign a generated winner or score.
- Protocol design significantly impacts the CJC-1295 no DAC & Ipamorelin results timeline. Here's how different dosing strategies and administration frequencies affect endpoint expression:
- CJC-1295 no DAC 100 mcg + Ipamorelin 100 mcg once daily (pre-sleep)
- Single nocturnal pulse mimicking endogenous rhythm
- Detectable at 7–10 days, plateau by week 3
- Visible at weeks 3–4
- 1–2 kg by week 8
- Standard research protocol. Aligns with circadian GH secretion, minimizes receptor desensitization. Best for sustained multi-week studies.
- CJC-1295 no DAC 200 mcg + Ipamorelin 200 mcg once daily
- Larger amplitude pulse, longer-duration IGF-1 elevation
- Detectable at 5–7 days, plateau by week 2
- Visible at weeks 2–3
- 1.5–3 kg by week 8
- Higher dosing accelerates timeline by 7–10 days but increases risk of localized injection site reactions and transient hyperglycemia in susceptible subjects.
- Twice-daily split dose (morning + pre-sleep, 100 mcg each compound per dose)
- Two pulses per day
- Faster plateau (week 2) and higher sustained IGF-1
- 2–3.5 kg by week 8
- Mimics physiological multi-pulsatile secretion pattern. Accelerates timeline but requires more frequent administration. Logistically complex for some lab models.
- CJC-1295 no DAC alone (no Ipamorelin), 200 mcg daily
- Single pathway GHRH stimulation
- Slower (10–14 days), lower peak IGF-1
- Visible at weeks 4–5
- 0.5–1.5 kg by week 8
- Monotherapy produces measurable but attenuated effects. The synergistic GH pulse amplification from dual-pathway activation is lost.
- Ipamorelin alone (no CJC-1295 no DAC), 200 mcg daily
- Ghrelin pathway only
- Moderate (7–10 days)
- Ipamorelin monotherapy works but lacks the sustained GHRH receptor activation that CJC-1295 no DAC provides. Results plateau earlier.
- The combination of CJC-1295 no DAC and Ipamorelin consistently outperforms either compound alone across every measured endpoint, which is why most research protocols default to stacked administration. The CJC-1295 no DAC & Ipamorelin results timeline shortens by 30–40% when both pathways are activated simultaneously.